secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001104659-24-060221
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Milestone restarts PSVT NDA for etripamil; cash of $89.5M funds into 2026
-------------------------------------------------------------------------

- NDA for etripamil in PSVT resubmitted after FDA Type A meeting; standard review expected, potential approval in H1 2025.
- Cash, equivalents and short-term investments of $89.5M as of March 31, 2024, expected to fund operations into 2026.
- No revenue in Q1 2024 vs $1.0M in Q1 2023; net loss of $10.4M improved from $15.0M a year ago.
- R&D expense fell to $3.6M from $10.3M due to completion of Phase 3 PSVT studies.
- March 2024 public offering of common shares and pre-funded warrants raised net proceeds of ~$32.2M for development and commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465924060221/0001104659-24-060221-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465924060221/tm2414191d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-060221

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer